Weber, Martin S.

Type II monocytes modulate T cell–mediated central nervous system autoimmune disease

Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine

Multiple Sclerosis Research StudiesT-cell and B-cell Immunology

Cited by 447

Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis

Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 324

CD 14 is a key organizer of microglial responses to CNS infection and injury

Janova, H., Böttcher, C., Holtman, I. R., Regen, T., van Rossum, D., Götz, A., Ernst, A., Fritsche, C., Gertig, U., Saiepour, N., et al. (2016) · Glia

Neuroinflammation and Neurodegeneration MechanismsImmune Response and Inflammation

Cited by 105

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice

Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E. (2007) · Current Opinion in Neurology

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 46

Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?

Geladaris, A., Torke, S., & Weber, M. S. (2022) · CNS Drugs

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 45

Concurrent axon and myelin destruction differentiates X-linked adrenoleukodystrophy from multiple sclerosis

Bergner, C. G., Genc, N., Hametner, S., Franz, J., van der Meer, F., Mitkovski, M., Weber, M. S., Stoltenburg‐Didinger, G., Kühl, J., Köhler, W., et al. (2021) · Glia

Multiple Sclerosis Research StudiesLysosomal Storage Disorders Research

Cited by 23

Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Montalban, X., Piasecka-Stryczynska, K., Kuhle, J., Benkert, P., Arnold, D. L., Weber, M. S., Seitzinger, A., Guehring, H., Shaw, J., Tomic, D., et al. (2024) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 21